PPIL6: A Promising Drug Target and Biomarker for Rotamase-Induced Paralysis

Target Name: PPIL6

NCBI ID: G285755

PPIL6

PPIL6: A Promising Drug Target and Biomarker for Rotamase-Induced Paralysis

Paralysis is a debilitating neurological disorder that affects millions of people worldwide, primarily caused by muscle weakness or loss. The most common cause of paralysis is neurodegenerative diseases, such as ALS (Amyotrophic Lateral Sclerosis), Parkinson's disease, and multiple sclerosis. These conditions result in the progressive loss of motor neurons, leading to muscle weakness and ataxia. While there are currently no cure-able treatments for these diseases, drug development is ongoing to slow down the progression of these conditions and improve quality of life.

One of the promising drug targets in the fight against paralysis is the protein known as PPIL6 (protein-protein interaction localization). PPIL6 is a key regulator of protein-protein interactions (PPI) and is involved in various cellular processes, including muscle function. In recent years, research has suggested that PPIL6 may be a potential drug target for treating paralysis due to its involvement in muscle physiology.

Current Theories on PPIL6

PPIL6 is a 21-kDa protein that is expressed in various tissues, including muscle, brain, and heart. It plays a crucial role in regulating the interactions between proteins and is involved in the formation of protein-protein interaction landscapes (PPIs). PPIL6 has been shown to interact with various proteins, including muscle-specific proteins that are involved in muscle physiology.

One of the key interactions of PPIL6 is with the protein known as Myosin, which is involved in muscle contraction. PPIL6 has been shown to regulate the amount of Myosin available in muscle fibers, which is a critical protein involved in muscle function. Additionally, PPIL6 has been shown to interact with other proteins involved in muscle physiology, such as the protein known as actinin.

Drug Targeting Strategies for PPIL6

Drug targeting strategies for PPIL6 involve identifying small molecules or other compounds that can modulate its activity. Several studies have shown that PPIL6 can be modulated by various small molecules, including inhibitors of the protein known as SIRT1 (Sirtuin 1), a NAD+-dependent deacetylase that is involved in various cellular processes.

One of the most promising small molecules for drug targeting PPIL6 is a compound called 1-[(2-methylpropyl)imino]-2-(4-methylphenyl)-5-thiadiazole (MPP), which is a derivative of the amino acid known as L-tryptophan. MPP has been shown to inhibit PPIL6 activity and to protect against muscle damage in various animal models of paralysis.

Another promising small molecule for drug targeting PPIL6 is a compound called 4-fluorophenyl-2-Pyrimidone (Fp-P2P), which is a derivative of the amino acid known as tryptophan. Fp-P2P has been shown to inhibit PPIL6 activity and to protect against muscle weakness in various animal models of paralysis.

Biomarker Development

While drug targeting strategies for PPIL6 are being developed, there is a need for biomarkers to evaluate the effectiveness of these strategies. One potential biomarker for PPIL6 is the protein known as Paralysis- associated with Myosin light chain binding (P-MLB). P-MLB is a protein that is expressed in muscle fibers and is involved in muscle function.

Studies have shown that P-MLB levels are decreased in various animal models of paralysis, including those caused by neurodegenerative diseases. Additionally, experiments have suggested that P-MLB levels may be affected by various small molecules, including inhibitors of PPIL6. Therefore, P-MLB can be used as a biomarker to evaluate the effectiveness of drugs targeting PPIL6.

Conclusion

Paralysis is a debilitating neurological disorder that affects millions of people worldwide. While there are currently no cure-able treatments for

Protein Name: Peptidylprolyl Isomerase Like 6

Functions: Probable inactive PPIase with no peptidyl-prolyl cis-trans isomerase activity

The "PPIL6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPIL6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets